Abstract:During the past several years, important advances have been made in our understanding of the mechanisms that regulate the expression of genes that determine drug clearance, including phase I and phase II drug-metabolising enzymes and drug transporters. Orphan nuclear receptors have been recognised as key mediators of drug-induced changes in both metabolism and efflux mechanisms. In this review, we summarise recent findings regarding the function of nuclear receptors in regulating drug-metabolising and transport systems, and the relevance of these receptors to clinical drug-drug interactions and the development of new drugs. Emphasis is given to two newly recognised ‘orphan’ receptors (the pregnane X receptor [PXR] and the constitutive androstane receptor [CAR]) and their regulation of cytochrome P450 enzymes, such as CYP3A4, CYP2Cs and CYP2B6; and transporters, such as P-glycoprotein (MDR1), multidrug resistance-associated proteins (MRPs) and organic anion transporter peptide 2 (OATP2). Although ‘cross-talk’ occurs between these two receptors and their target sequences, significant species differences exist between ligand-binding and activation profiles for both receptors, and PXR appears to be the predominant or ‘master’ regulator of hepatic drug disposition in humans. Several important physiological processes, such as cholesterol synthesis and bile acid metabolism, are also tightly controlled by certain ligand-activated orphan nuclear receptors (farnesoid X receptor [FXR] and liver X receptor [LXR]). In general, their ability to bind a broad range of ligands and regulate an extensive array of genes that are involved in drug clearance and disposition makes these orphan receptors attractive targets for drug development. Drugs have the capacity to alter nuclear receptor expression (modulators) and/or serve as ligands for the receptors (agonists or antagonists), and thus can have synergistic or antagonistic effects on the expression of drug-metabolising enzymes and transporters. Coadministration of drugs that are nuclear receptor agonists or antagonists can lead to severe toxicity, a loss of therapeutic efficacy or an imbalance in physiological substrates, providing a novel molecular mechanism for drug-drug interactions.

Regulation of Brain Drug Metabolizing Enzymes and Transporters by Nuclear Receptors

Function of Nuclear Receptor in Drug Metabolism

Regulation of the ATP-binding cassette transporters ABCB1, ABCG2 and ABCC5 by nuclear receptors in porcine blood-brain barrier endothelial cells

Xenobiotic-sensing nuclear receptors involved in drug metabolism: a structural perspective

Nuclear Xenobiotic Receptors: Integrating Gene Regulation to Physiological Functions

Research status of microRNA-dependent control of drug metabolic enzymes and transporters mediated by nuclear receptors

Regulation of Nuclear Receptors on Cytochrome P450 Enzymes

ABC transporter regulation by signaling at the blood-brain barrier: relevance to pharmacology

Chapter 3 Nuclear Xenobiotic Receptors

Role of Orphan Nuclear Receptors in the Regulation of Drug-Metabolising Enzymes

Regulation of Drug-Metabolizing Enzymes by Xenobiotic Receptors: PXR and CAR

Regulation of ABC transporters blood-brain barrier: the good, the bad, and the ugly

Relationship Between ABC Transporters on the Blood-Brain Barrier and Central Nervous Diseases

The potential impact of CYP and UGT drug-metabolizing enzymes on brain target site drug exposure

Minireview: Nuclear Receptor-Controlled Steroid Hormone Synthesis and Metabolism.

Structural Overview and Perspectives of the Nuclear Receptors, a Major Family As the Direct Targets Forsmall-Molecule Drugs

Safety Implications of Modulating Nuclear Receptors: A Comprehensive Analysis from Non-Clinical and Clinical Perspectives

Botanical Compounds and Their Regulation of Nuclear Receptor Action: the Case of Traditional Chinese Medicine.

Non-cytochrome P450 Enzymes Involved in the Oxidative Metabolism of Xenobiotics: Focus on the Regulation of Gene Expression and Enzyme Activity.

Nuclear Receptors PXR and CAR: Implications for Drug Metabolism Regulation, Pharmacogenomics and Beyond

Influence factors on and potential strategies to amplify receptor-mediated nanodrug delivery across the blood–brain barrier